With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5676-60-8,2-Methylbenzo[d]oxazol-6-amine,as a common compound, the synthetic route is as follows.
To a stirred solution of 5,7-dimethylpyrazolo[l,5-a]pyrimidine-3-carboxylic acid 2 (50 mg, 0.262 mmol), 2-methyl-l,3-benzoxazol-6-amine (47 mg, 0.314 mmol) and HATU (149 mg, 0.393 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.524 mmol), and the reaction mixture was stirred at room temperature for 16 hours until the reaction was complete. The suspension was diluted with H20 (3 mL), and the precipitated solid was collected by filtration, washed with minimum DCM and Et20, and dried in vacuo to provide the title compound (60 mg, 71%) as a white solid.XH NMR (400 MHz, DMSO-i/6) delta 10.36 (s, 1H), 8.66 (s, 1H), 8.31 (d, J= 2.0 Hz, 1H), 7.64 (d, J= 8.4 Hz, 1H), 7.47 (dd, J= 8.4 Hz, 2.0 Hz, 1H), 7.21 (s, 1H), 2.78 (s, 3H), 2.73 (s, 3H), 2.60 (s, 3H). ES-MS m/z: 322.0 [M+H]+. LC-MS Purity (254 nm): >99%; tR= 1.74 min.
As the paragraph descriping shows that 5676-60-8 is playing an increasingly important role.
Reference£º
Patent; LYSOSOMAL THERAPEUTICS INC.; SKERLJ, Renato, T.; LANSBURY, Peter, T.; GOOD, Andrew, C.; BOURQUE, Elyse, Marie Josee; (139 pag.)WO2016/73895; (2016); A1;,
Benzoxazole – Wikipedia
Benzoxazole | C7H5NO – PubChem